| Pub. Date | : July, 2023 |
|---|---|
| Product Name | : The IUP Journal of Knowledge Management |
| Product Type | : Article |
| Product Code | : IJKM030723 |
| Author Name | : Hadiya Faheem and Sanjib Dutta |
| Availability | : YES |
| Subject/Domain | : Management |
| Download Format | : PDF Format |
| No. of Pages | : 29 |
The case discusses the failure of International Business Machines' (IBM) artificial intelligence (AI) software Watson for Oncology (Watson). In 2012, the American multinational technology company partnered with New York-based cancer treatment center and research organization Memorial Sloan Kettering Cancer Center (MSK) to develop Watson that could provide medical professionals with improved access to up-to-date and comprehensive cancer data and practices. Despite Watson's Natural Language Processing (NLP) ability that enabled it to read and gain insights from unstructured data it was not able to interpret data as human doctors could. A 2017 investigation carried out by news website STAT revealed how IBM's AI software could not live up to the hype created around it by the company. To add to IBM's troubles, a 2017 audit carried out by the University of Texas showed that MD Anderson was using old data to train its OEA. The same year, i.e. in 2017, the cancer center closed down its project with IBM after spending $62 mn. With data quality and domain expertise being some of the major reasons for the failure of AI projects, is it worth it for companies such as IBM to invest in AI and Machine Learning (ML) tools in healthcare like Watson for Oncology without proper data preparation? This study looks at the roadblocks standing in the way of IBM finding success in using AI and ML in a bid to drive clinical research and drug discovery. It also examines how technology companies can make AI and ML a truly transformative force in healthcare.
I believe that we're many years away from AI products that really positively impact clinical care for many patients.i
- Bob Kocher,
Partner at California-based venture-capital firm Venrock, in February 2021
Merely proving that you have powerful technology is not sufficient. Prove to me that it will actually do something useful-that it will make my life better, and my patients' lives better.ii
- Martin Kohn, a former IBM medical scientist, in April 2019
IBM's attempt to promote its supercomputer programme to cancer doctors (Watson for Oncology) was a PR disaster. The problem with Watson for Oncology was that doctors simply didn't trust it.iii
- Vyacheslav Polonski, UX1 researcher for Google
and founder of data science agency Avantgarde Analytics, in September 2018
In June 2019, American multinational technology company International Business Machines Corporation (IBM)'s business unit, IBM Watson Health2, in association with its partners,